JournalsHub
.online
Find My Journal
ÁR

Ángel Rodríguez

Universitat Autònoma de Barcelona ES

ORCID 0000-0001-8721-9539
68
Publications
2,474
Citations
19
H-Index
30
i10-Index
11.84
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P. Frías, Laura Fernández Landó +3 more
The Lancet 2021
574
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes OA
Dominik Dahl, Yukiko Onishi, Paul Norwood, Ruth Huh, Ross Bray +2 more
JAMA 2022
529
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers +1 more
The Lancet Diabetes & Endocrinology 2022
444
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial
Achim J. Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez‐Baño, José Miguel Cisneros, M.D. Navarro +61 more
The Lancet Infectious Diseases 2024
75
Prevalencia y factores asociados a los acontecimientos adversos prevenibles por medicamentos que causan el ingreso hospitalario OA
María José Otero López, P. Alonso Hernández, A. Fernández, J. Ceruelo Bermejo, Alfonso Domínguez-Gil Hurlé +1 more
Farmacia Hospitalaria 2006
55

Publications

62 total

Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial PDF

Naveed Sattar, Ian J. Neeland, Olof Dahlqvist Leinhard, Laura Fernández Landó, Ross Bray et al. - The Lancet Diabetes & Endocrinology, 2025
Cited by 55 OpenAlex

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Achim J. Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez‐Baño, José Miguel Cisneros, M.D. Navarro et al. - The Lancet Infectious Diseases, 2024
Cited by 75 OpenAlex

Incretin-based investigational therapies for the treatment of MASLD/MASH PDF

Bram Brouwers, Girish S. Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C. Glass et al. - Diabetes Research and Clinical Practice, 2024
Cited by 32 OpenAlex

Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes PDF

Bertrand Cariou, Jennifer Linge, Ian J. Neeland, Olof Dahlqvist Leinhard, Mikael Petersson et al. - Diabetes Obesity and Metabolism, 2024
Cited by 25 OpenAlex

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1–4 PDF

Maciej T. Małecki, Rachel L. Batterham, Naveed Sattar, Joshua A. Levine, Ángel Rodríguez et al. - Diabetes Care, 2023
Cited by 44 OpenAlex

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials PDF

Julio Rosenstock, Luis Alberto Vázquez, Stefano Del Prato, Denise Reis Franco, Govinda J. Weerakkody et al. - Diabetes Care, 2023
Cited by 36 OpenAlex

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the <scp>SURPASS</scp> clinical trials PDF

Hiren Patel, Kamlesh Khunti, Helena W. Rodbard, Harpreet S. Bajaj, Ross Bray et al. - Diabetes Obesity and Metabolism, 2023
Cited by 29 OpenAlex

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes PDF

Dominik Dahl, Yukiko Onishi, Paul Norwood, Ruth Huh, Ross Bray et al. - JAMA, 2022
Cited by 529 OpenAlex

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers et al. - The Lancet Diabetes & Endocrinology, 2022
Cited by 444 OpenAlex

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P. Frías, Laura Fernández Landó et al. - The Lancet, 2021
Cited by 574 OpenAlex

Research Topics

Diabetes Treatment and Management (37) Diabetes Management and Research (24) Metabolism, Diabetes, and Cancer (19) Diet and metabolism studies (10) Pharmacology and Obesity Treatment (7)

Frequent Co-Authors

RO
Ross Bray
6 joint publications
LA
Laura Fernández Landó
5 joint publications
HI
Hiren Patel
2 joint publications
BR
Bram Brouwers
2 joint publications
NA
Naveed Sattar
2 joint publications
IA
Ian J. Neeland
2 joint publications

Affiliations

Universitat Autònoma de Barcelona
ES 2025 - 2025
Eli Lilly (United States)
US 2025 - 2010
Hospital de Sant Pau
ES 2025 - 2025
Research Institute Hospital 12 de Octubre
ES 2025 - 2025
Biomedical Research Networking Center on Neurodegenerative Diseases
ES 2025 - 2025

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now